New Alzheimer’s Drug Offered in Vero Beach

Dr. Sikora Now Administering TB006 Under Compassionate Use

Vero Beach, FL – May 28, 2025

In an advancement for local Alzheimer’s care, Dr. Alita Sikora of Sikora Integrative Medicine has been officially selected to administer TB006, a groundbreaking investigational therapy, through the FDA’s Compassionate Use Program. Her clinic is now one of the few nationwide approved to offer this treatment to eligible patients.

This announcement marks a major step in Sikora Integrative Medicine’s mission to bring innovative, evidence-based treatments to the Vero Beach community.

Alzheimer’s: A National Health Emergency

Alzheimer’s disease is a complex neurodegenerative condition currently affecting 7 million Americans.

Roughly two-thirds of those diagnosed are women, making this a gender-disproportionate crisis. By 2050, it is projected that more than 13 million people will be living with the disease in the U.S.

Why Alzheimer’s is so impactful:

• 5th leading cause of death in adults 65+
• 11+ million unpaid caregivers support loved ones
• Projected $1 trillion in annual care costs by 2050

These statistics illustrate why medical innovation is desperately needed. According to a recent article by Vero News, researchers are optimistic about TB006’s potential to change the trajectory of the disease for many patients.

How TB006 Works: A Targeted Solution

TB006 is a humanized monoclonal antibody that targets galectin-3 (GAL-3)—a protein known to contribute to the formation of amyloid plaques and tau tangles in the brain. These protein clusters disrupt neuronal communication and accelerate cognitive decline.

TB006’s unique dual-action mechanism:

• Inhibits GAL-3, preventing further neurotoxic buildup
• Promotes the dissolution of existing plaques and tangles
• Supports restoration of neuronal function and cognition

While still in investigational phases, TB006 represents a potential disease-modifying treatment, rather than one that simply manages symptoms.

Encouraging Early Results

Initial clinical trials have shown significant promise:

• 47% of patients demonstrated cognitive improvement after 3 months
• 28% saw stabilization of memory and thinking skills
• Participants tolerated the treatment well with minimal adverse effects

Patient outcomes are continuously monitored, and anonymized data is submitted to the FDA and the manufacturer to help refine future applications of the therapy.

Who Qualifies for TB006 Treatment?

Because TB006 is offered under compassionate use, strict criteria must be met to ensure patient safety and optimal outcomes.

Eligibility requirements include:

• Age 55 or older
• MMSE score of 24 or lower
• Inability to tolerate or failure of standard Alzheimer’s therapies

Treatments are administered monthly via intravenous infusion at Sikora Integrative Medicine’s Vero Beach clinic. Each session includes:

• Careful clinical supervision
• Continuous monitoring of cognitive function
• Personalized care coordination with patients and families

Why Dr. Alita Sikora?

Dr. Sikora has long been a trusted provider of integrative and regenerative medicine. She received her medical degree from the University of Connecticut School of Medicine and completed residency training in Physical Medicine and Rehabilitation at NewYork-Presbyterian Hospital—affiliated with Columbia and Cornell.

Her qualifications for TB006 include:

• Approval by an Institutional Review Board (IRB)
• Specialized training in administering the therapy
• Years of experience combining modern science with holistic care

This blend of credentials, experience, and compassion is what earned Dr. Sikora this important opportunity to deliver TB006 to the local community.

Want a Deeper Dive into TB006?

If you're looking for a more in-depth explanation of how TB006 works, the science behind galectin-3 inhibition, or the FDA’s Expanded Access Program process, we've covered that extensively in a previous post.

Read more here: TB006 for Dementia Now Available Through Expanded Access

This earlier article provides greater clinical detail, including:

• Mechanisms of action explained in patient-friendly language
• A breakdown of current and past Alzheimer’s drug classes
• Insights into the ethical and logistical aspects of compassionate use protocols

Whether you're a caregiver, patient, or clinician, this deeper resource is designed to answer the questions many readers have about investigational therapies like TB006.

Accessing TB006 in Vero Beach

Patients and families interested in exploring TB006 can schedule an initial consultation to determine eligibility and understand treatment logistics.

Contact Sikora Integrative Medicine

• Call: 772-837-5440
• Address: 1255 37th Street, Suite B, Vero Beach, FL
• Visit: sikoramedical.com